Keryx Biopharma (KERX) Reports In-Line Q2 EPS

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 11/4/2026

1. AMD
2. BKNG
3. AMGN
4. DOX
5. DUOL
6. ANET
7. SWKS
8. SPY
9. XYZ
10. FISV

Go back to Keryx Biopharma (KERX) Reports In-Line Q2 EPS

Keryx Biopharmaceuticals Announces Second Quarter 2015 Financial Results

August 5, 2015 7:01 AM EDT

Majority of phosphate binder patients today have access to Auryxia

CHMP recently adopted a positive opinion for Fexeric® (ferric citrate coordination complex) in the EU

Enrollment complete in ongoing Phase 3 label-expansion study for Auryxia

BOSTON, Aug. 5, 2015 (GLOBE NEWSWIRE) -- Keryx Biopharmaceuticals, Inc. (Nasdaq: KERX), a biopharmaceutical company focused on bringing innovative therapies to market for people with renal disease, today announced its financial results for the second quarter ended June 30, 2015.

"We are making progress on several important milestones across our... More